Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences (CSTL) reported continued momentum in its core diagnostic franchises in Q2, leading management to raise its outlook. The CFO, Frank Stokes, said the increase exceeded the magnitude of the company’s reported earnings beat, signaling stronger forward demand than previously expected.

Analysis

Castle Biosciences (CSTL) reported continued momentum in its core diagnostic franchises in Q2, leading management to raise its outlook. The CFO, Frank Stokes, said the increase exceeded the magnitude of the company’s reported earnings beat, signaling stronger forward demand than previously expected.